L858R EGFR mutation status correlatedwith clinico-pathological features of japanese lung cancer

Lung Cancer

Volumn 54, Issue 1, 2006, Pages 103-108

  Sasaki, Hidefumi ^a   Endo, Katsuhiko ^a   Takada, Minoru ^b   Kawahara, Masaaki ^b   Kitahara, Naoto ^b   Tanaka, Hisaichi ^b   Okumura, Meinoshin ^b   Matsumura, Akihide ^b   Iuchi, Keiji ^b   Kawaguchi, Tomoya ^b   Yukiue, Haruhiro ^a   Kobayashi, Yoshihiro ^a   Yano, Motoki ^a   Fujii, Yoshitaka ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

Author keywords

EGFR; Exon 19; L858R; Lung cancer; Mutations

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADENOCARCINOMA; AGED; ARTICLE; ENZYMOLOGY; EXON; FEMALE; GENETICS; GENOTYPE; HUMAN; JAPAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; MUTATION; NONPARAMETRIC TEST; PATHOLOGY; STATISTICAL MODEL; SURVIVAL RATE;

ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; EXONS; FEMALE; GENOTYPE; HUMANS; JAPAN; LINEAR MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STATISTICS, NONPARAMETRIC; SURVIVAL RATE;

EID: 34548457225     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.06.003     Document Type: Article

References (23)

1. Ginsberg RJ, Kris K, Armstrong G. Cancer of the lung. In: Principles and practice of oncology. 4th ed. Philadelphia: Lippincott; 1993. p. 673-82.
2. Nicolson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37:S9-S15.
3. Onn A, Correa AM, Gilcrease M, Isobe T, Massarelli E, Bucane CD, et al. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 2004;10:136-43.
4. Kris MG, Natale RB, Herbst RS, Lynch Jr TJ, Prager D, Belan CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non small cell lung cancer: randomized trial. JAMA 2003;290:2149-58.
5. Thatcher N, Chang A, Purvish P, Perreiro JR, Ciuleanu T, van Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advance non-small-cell lung cancer: result from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-37.
6. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21: 2237-46.
7. Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004;22:1103-9.
8. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
9. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. New Eng J Med 2004;350: 2129-39.
10. Kasaoka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-23.
11. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Witsub II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutation in lung cancers. J Natl Cancer Inst 2005;97:336-9.
12. Tokumo M, Toyooka S, Kiura K, Shigematsu H, Tomii K, Aoe M, et al. The relationship between epidermal growth factor receptor mutation and clinicopathological feature in non-small cell lung cancers. Clin Cancer Res 2005;11:1167-73.
13. Endo K, Konishi A, Sasaki H, Takada M, Tanaka H, Okumura M, et al. Epidermal growth factor receptor gene mutation in nonsmall cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer 2005;50:375-84.
14. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from "never smokers"and are associated with sensitivity of tumors to gefitinib and elrotinib. Proc Natl Acad Sci 2004;101:13306-11.
15. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Onlol 2005;23:857-65.
16. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, et al. Mutation of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23:2513-20.
17. Moriguchi H, Kim T-Y, Sato C. Gefitinib for refractory advanced non-small-cell lung cancer. Lancet 2006;367:299.
18. Sugio K, Uramoto H, Ono K, Oyama T, Hanagiri T, Sugaya M, et al. Mutations with the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tabacco smoking. Eur J Cancer 2006;94:896-903.
19. Sasaki H, Endo K, Konishi A, Takada M, Kawahara M, Iuchi K, et al. EGFR mutation status in Japanese lung cancer patients: genotyping analysis using LighyCycler. Clin Cancer Res 2005;11:2924-9.
20. Sasaki H, Shimizu S, Endo K, Takada M, Kawahara M, Tanaka H, et al. EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer 2006;118:180-4.
21. Gazdar AF, Shigematsu H, Herz J, Minna JD. Mutations and addiction to EGFR: the Acilles 'heal' of lung cancers? Trends Mol Med 2004;10:481-6.
22. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinibsensitizing EGFR mutations in lung cancer activated antiapoptotic pathways. Science 2005;305:1163-7.
23. Riely GJ, Pao W, Pham DK, Li AR, Rizvi N, Venkatraman ES, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006;12:839-44.